FDA Approval of Axi-Cel - 42% of patients have long-term durability

FDA Approval of Axi-Cel - 42% of patients have long-term durability

User Photo
ASHReport

2 years
727 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses FDA's approval of Axi-Cel and 42% of patients have long-term durability at the 2017 American Society of Hematology.
Up Next Autoplay